Hospital Acquired Pneumonia Prevention Market Expected to be Valued US$ 1,100 Mn by 2026

Hospital Acquired Pneumonia Prevention Market to Exceed US$ 1,100 Mn by 2026
Over an eight-year period of assessment 2018-2026, the global market for hospital-acquired
pneumonia prevention is poised to witness moderate growth, according to a recent research report
on the global hospital-acquired pneumonia prevention market. The report has been published by
Persistence Market Research and is titled, “Hospital-Acquired Pneumonia Prevention Market:
Global Industry Analysis 2013 – 2017 and Forecast 2018 – 2026.” The US$ 795 Mn market is
likely to exhibit a CAGR of 4.7%, reaching a value in excess of US$ 1,100 Mn by the end of 2026.
Report overview @ https://www.persistencemarketresearch.com/market-research/hospital-acquiredpneumonia-prevention-market.asp
Key Market Drivers: Overview : Immunosenescence will continue to remain a key factor driving
the demand for prevention of hospital-acquired pneumonia worldwide. Expanding geriatric
population and the following ceasing immunity are expected to sustain the need for regulating the
pneumonia infection acquired in hospitals. Increasing cases of chronic ailments resulting in
gradually weakening immune system also mark another strong driver to market growth in next few
years. Ceasing immunity in turn extends patients’ stay at hospitals, which makes them more prone
to acquiring disease infections such as pneumonia. The global market for hospital-acquired
pneumonia prevention is anticipated to gain continued thrust from such instances, including people
of all age groups.
Request Sample Report @ https://www.persistencemarketresearch.com/samples/22768
Amplifying patient pool across the globe coupled with an increasing number of hospitals in
developed as well as developing economies are presumed to push the market scenario up in near
future. Moreover, several countries are mandating the implementation of pneumonia prevention
protocols, which is apprehended to create multiple growth opportunities in upcoming years. The
growth of market in developing economies will be specifically accelerated by soaring burden of
pneumonia instances among the Southeast Asian Countries. Medical tourism industry is flourishing
in emerging countries such as India is expected to fuel the hospital-acquired pneumonia cases and
thereby, elevate the demand for its prevention throughout the next few years.
Request Report TOC @ https://www.persistencemarketresearch.com/market-research/hospitalacquired-pneumonia-prevention-market/toc
Regional Analysis: Overview : Regional segmentation of the global hospital-acquired pneumonia
prevention classifies the market as North America, Latin America, Europe, Asia Pacific excluding
China, China, and Middle East & Africa. Among these, North America will remain dominant over
all other regional markets primarily owing to a favorable initiative by the US Government to
incentivize innovation in the field of antibacterial drugs. This governmental activity aims at
addressing the emergency demand for better prevention measures against bacterial infections.
Moreover, the demand for high-quality oral care products in ICU sections of hospitals has been
escalating due to rising chronic kidney disease instances since the recent past. Europe secures the
second position in terms of market size, APEC is foreseen to be the third largest lucrative region;
whereas China is projected to be the most promisingly emerging market with the largest estimated
CAGR value of around 5.5%.
Request Report Multiple Chapter @ https://www.persistencemarketresearch.com/multiplechapter/22768
Key Market Players: Overview : The leading companies operating the global market for hospitalacquired pneumonia prevention include Halyard Health, Inc., Sage Products LLC, Intersurgical
Ltd., Medline Industries, Inc., and others. Attributed to strong presence of a majority key players
such as Halyard Health, Inc., Medline Industries, Inc., and Stryker Corporation (SAGE Products
LLC) in the US has been crucially responsible to uplift the performance of North American market
for hospital-acquired pneumonia prevention over the years. As the number of dedicated companies
dealing in the industry are limited, the overall scenario will remain price sensitive over the next few
years.